49 results
8-K
EX-99.1
INVA
Innoviva Inc
13 May 24
Corporate Presentation May 2024
9:27am
- term upside Innovative anti - infectives R&D Armata has R&D and manufacturing capabilities along with a platform in bacteriophages, a new
8-K
EX-99.1
INVA
Innoviva Inc
8 May 24
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
4:44pm
. Innoviva’s other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including
8-K
EX-99.1
w8kjjdd6 4g
29 Feb 24
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
4:15pm
8-K
EX-99.1
abfvi3o9xw2pobi2gi4
1 Nov 23
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
4:30pm
8-K
EX-99.1
ni1cjp4etgmj82rsl2
2 Aug 23
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
4:15pm
8-K
EX-99.1
pb982
24 May 23
Corporate Presentation May 2023
5:18pm
8-K
EX-99.1
p7yzt8194
9 May 23
Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent
5:21pm
8-K
EX-99.1
e3ca2ivu8foa5ev0pb
14 Sep 22
Regulation FD Disclosure
5:22pm
SC TO-T/A
EX-99
q87gej7q20
22 Aug 22
Third party tender offer statement (amended)
9:08am
SC TO-T
EX-99
t5fk 074qi
25 Jul 22
Third party tender offer statement
8:34am
8-K
EX-99.1
ob9lzg66ctn5y9kbdjuy
13 Jul 22
Entry into a Material Definitive Agreement
5:27pm
SC TO-C
n54qzql
11 Jul 22
Information about tender offer
3:46pm